FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2372245829> ?p ?o ?g. }

• W2372245829 endingPage "1092" @default.
• W2372245829 startingPage "1085" @default.
• W2372245829 abstract "Object Intracranial aneurysms, especially those of the cavernous segment of the internal carotid artery (ICA), can present with cranial nerve (CN) palsies. The Pipeline Embolization Device (PED) has demonstrated safety and efficacy in the treatment of cerebral aneurysms by flow diversion, but little data exist reporting the outcomes of cranial neuropathies following treatment with the device. Methods The prospectively maintained Barrow Neurological Institute's endovascular database was reviewed for all patients treated with the PED after presenting with one or more CN palsies secondary to a cerebral aneurysm since May 2011. Patient charts and digital subtraction angiograms were reviewed to report clinical and angiographic outcomes. Only patients with clinical follow-up were included in the analysis. Results A total of 127 patients were treated with the PED at the authors' institution after FDA approval. Twentytwo patients presented with cranial neuropathies, for initial inclusion in this study. Of these, 20 had sufficient followup for analysis. Cranial neuropathies included those of CN II, III, V, and VI, with presenting symptoms of diplopia, decreased visual acuity, and facial numbness and/or pain. Thirteen lesions were cavernous segment ICA aneurysms, whereas the remainder included supraclinoid and petrous segment ICA, posterior communicating artery, and basilar trunk aneurysms. At an average clinical follow-up of 9.55 months, 15 patients (75%) had resolution or significant improvement of their cranial neuropathies, and the remaining 5 had stable symptoms. Of the 18 patients with angiographic follow-up, 12 (66.7%) demonstrated complete obliteration or small neck residual, whereas 6 (33.3%) had residual lesion. Patients with complete or near-complete obliteration of their lesion were significantly more likely to demonstrate symptomatic improvement at follow-up (p = 0.009). Two patients with persistent symptoms were eventually treated with microsurgical bypass. Transient complications in this series included 6 (30%) extracranial hemorrhagic complications related to dual-antiplatelet therapy, all of which were managed medically. There was 1 delayed right ICA occlusion following retreatment that led to microsurgical bypass. Conclusions Intracranial aneurysms presenting with one or more CN palsies show a high rate of clinical improvement after treatment with the PED. Clinical outcomes must be weighed against the risks and challenges faced with flow diverters. Further research is warranted for patients whose symptoms do not respond optimally to device placement." @default.
• W2372245829 created "2016-06-24" @default.
• W2372245829 creator A5022788776 @default.
• W2372245829 creator A5039738713 @default.
• W2372245829 creator A5054913656 @default.
• W2372245829 creator A5063559952 @default.
• W2372245829 creator A5071741375 @default.
• W2372245829 date "2014-11-01" @default.
• W2372245829 modified "2023-10-11" @default.
• W2372245829 title "Resolution of cranial neuropathies following treatment of intracranial aneurysms with the Pipeline Embolization Device" @default.
• W2372245829 cites W1971235373 @default.
• W2372245829 cites W1971404286 @default.
• W2372245829 cites W1978571919 @default.
• W2372245829 cites W1981411150 @default.
• W2372245829 cites W1987851908 @default.
• W2372245829 cites W2009656044 @default.
• W2372245829 cites W2038336463 @default.
• W2372245829 cites W2044760191 @default.
• W2372245829 cites W2056505530 @default.
• W2372245829 cites W2080075813 @default.
• W2372245829 cites W2087329882 @default.
• W2372245829 cites W2104500225 @default.
• W2372245829 cites W2115859208 @default.
• W2372245829 cites W2117199250 @default.
• W2372245829 cites W2122648476 @default.
• W2372245829 cites W2126474227 @default.
• W2372245829 cites W2131611718 @default.
• W2372245829 cites W2151682975 @default.
• W2372245829 cites W2153361046 @default.
• W2372245829 cites W2158557877 @default.
• W2372245829 cites W2160108890 @default.
• W2372245829 cites W2168468058 @default.
• W2372245829 cites W2313729572 @default.
• W2372245829 cites W4256110463 @default.
• W2372245829 doi "https://doi.org/10.3171/2014.7.jns132677" @default.
• W2372245829 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25192477" @default.
• W2372245829 hasPublicationYear "2014" @default.
• W2372245829 type Work @default.
• W2372245829 sameAs 2372245829 @default.
• W2372245829 citedByCount "42" @default.
• W2372245829 countsByYear W23722458292015 @default.
• W2372245829 countsByYear W23722458292016 @default.
• W2372245829 countsByYear W23722458292017 @default.
• W2372245829 countsByYear W23722458292018 @default.
• W2372245829 countsByYear W23722458292019 @default.
• W2372245829 countsByYear W23722458292020 @default.
• W2372245829 countsByYear W23722458292021 @default.
• W2372245829 countsByYear W23722458292022 @default.
• W2372245829 countsByYear W23722458292023 @default.
• W2372245829 crossrefType "journal-article" @default.
• W2372245829 hasAuthorship W2372245829A5022788776 @default.
• W2372245829 hasAuthorship W2372245829A5039738713 @default.
• W2372245829 hasAuthorship W2372245829A5054913656 @default.
• W2372245829 hasAuthorship W2372245829A5063559952 @default.
• W2372245829 hasAuthorship W2372245829A5071741375 @default.
• W2372245829 hasConcept C126838900 @default.
• W2372245829 hasConcept C141071460 @default.
• W2372245829 hasConcept C2776035437 @default.
• W2372245829 hasConcept C2776098176 @default.
• W2372245829 hasConcept C2778034410 @default.
• W2372245829 hasConcept C2778286760 @default.
• W2372245829 hasConcept C2778333808 @default.
• W2372245829 hasConcept C2780540156 @default.
• W2372245829 hasConcept C2780581723 @default.
• W2372245829 hasConcept C2780643987 @default.
• W2372245829 hasConcept C2909310872 @default.
• W2372245829 hasConcept C71924100 @default.
• W2372245829 hasConceptScore W2372245829C126838900 @default.
• W2372245829 hasConceptScore W2372245829C141071460 @default.
• W2372245829 hasConceptScore W2372245829C2776035437 @default.
• W2372245829 hasConceptScore W2372245829C2776098176 @default.
• W2372245829 hasConceptScore W2372245829C2778034410 @default.
• W2372245829 hasConceptScore W2372245829C2778286760 @default.
• W2372245829 hasConceptScore W2372245829C2778333808 @default.
• W2372245829 hasConceptScore W2372245829C2780540156 @default.
• W2372245829 hasConceptScore W2372245829C2780581723 @default.
• W2372245829 hasConceptScore W2372245829C2780643987 @default.
• W2372245829 hasConceptScore W2372245829C2909310872 @default.
• W2372245829 hasConceptScore W2372245829C71924100 @default.
• W2372245829 hasIssue "5" @default.
• W2372245829 hasLocation W23722458291 @default.
• W2372245829 hasLocation W23722458292 @default.
• W2372245829 hasOpenAccess W2372245829 @default.
• W2372245829 hasPrimaryLocation W23722458291 @default.
• W2372245829 hasRelatedWork W1986242791 @default.
• W2372245829 hasRelatedWork W2031970382 @default.
• W2372245829 hasRelatedWork W2062178061 @default.
• W2372245829 hasRelatedWork W2158885453 @default.
• W2372245829 hasRelatedWork W2348347034 @default.
• W2372245829 hasRelatedWork W2371776335 @default.
• W2372245829 hasRelatedWork W2375904238 @default.
• W2372245829 hasRelatedWork W2810703900 @default.
• W2372245829 hasRelatedWork W2882992296 @default.
• W2372245829 hasRelatedWork W3032639658 @default.
• W2372245829 hasVolume "121" @default.
• W2372245829 isParatext "false" @default.
• W2372245829 isRetracted "false" @default.
• W2372245829 magId "2372245829" @default.

• next